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ABSTRACT
Background: Fluorouracil (5-FU) is a pyrimidine analogue used as a cancer
reatment. Its toxic side effects, including mucositis, are reported to occur in 40% of
he treated patients. Because of the inflammatory component of mucositis, we
xplored the possibility of modulating this condition with an immunomodulatory
gent and a tumor necrosis factor- inhibitor.
Objective: The aim of this study was to evaluate the effect of 2 immunosup-
pressive agents, etanercept and cyclosporine, in a murine model of 5-FU–induced
mucositis.
Methods: To study the short-term effects of 5-FU on mucositis, cyclosporine
and etanercept were administered to mice after an injection of 5-FU. The animals
(n  8) were euthanized at 6 hours post-challenge. Hematoxylin and eosin–stained
histologic sections of the small intestine were examined for signs of apoptosis. To
further examine the potential of cyclosporine in the treatment of 5-FU–induced
mucositis in a longer duration, the animals (N 15) were given 2 challenges of 5-FU
ithin 6 hours. All mice were dosed daily until day 9 with either cyclosporine (100
g/kg) or phosphate-buffered saline (PBS).
Results: Six hours after 5-FU challenge, 25 mg/kg etanercept and 50 mg/kg
cyclosporine had no effect on 5-FU–induced apoptosis (P  0.05). However, 100
mg/kg cyclosporine significantly reduced the cumulative level of apoptosis 41.6%
of the intestinal crypt surface (P  0.05). During long-term observation, all mice
began to lose weight at a rate of approximately 0.8 g/day after 5-FU exposure. The
rates of weight loss and survival were not affected by cyclosporine treatment. The
diarrhea onset began on day 4 with 46.7% of the PBS-treated mice showing signs of
diarrhea compared with 53.3% in the cyclosporine group. The diarrhea score for both
groups plateaued on day 7, with a cumulative score of 41 for the PBS group and 50
for the cyclosporine group. Cyclosporine treatment did not affect the diarrhea onset
day or severity compared with the PBS-treated group (P  0.05).
Conclusions: Our data indicated that etanercept is not a suitable treatment for
5-FU–induced mucositis. Despite decreased apoptosis in the gut, cyclosporine did not
affect the severity of the diarrhea or survival. Therefore, we concluded that cyclosporine
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D. Tung et al.treatment was only effective in mediating the short-term apoptotic events in the intestines
but has no long-term effect on the animals’ survival and diarrhea. (Curr Ther Res Clin Exp.
2011;72:262–272)
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INTRODUCTION
Fluorouracil (5-FU) is a pyrimidine analogue that has been used as cancer therapy
since the 1960s.1 It is an irreversible inhibitor of thymidylate synthase that is
involved in DNA replication and repair. It inhibits the activity of the exosome
complex and can incorporate its toxic metabolites into DNA and RNA, leading to
cell cycle arrest and apoptosis.2 This mechanism of action also affects rapidly dividing
healthy cells in the patients and causes a variety of side effects including mucositis.
This compound was used successfully to induce gastrointestinal mucositis in both
relevant mouse and rat models.3–5 In these models, the decrease in diarrhea correlated
ell with the reduction of intestinal inflammation and crypt cell survival.
During the pathogenesis of mucositis, epithelial damage caused by the initial
nsult is followed by local cytokine production, which leads to inflammation followed
y ulceration.6 There are multiple lines of evidence that point to an inflammatory
component in mucositis. Nuclear factor B (NF-B), cyclooxygenase-2 (COX-2), and
proinflammatory cytokines such as interleukin 1 beta (IL-1), IL-6, and tumor
ecrosis factor  (TNF-) have been linked to the pathogenesis of mucositis.6–8 The
ncrease in TNF- production is well documented.9,10 It can activate NF-B and
ause the release of other proinflammatory cytokines, thus amplifying the signal.8,9
Because of this reason, the damaging effects caused by TNF- release extend beyond
the initial insult. In addition to its proinflammatory effects, TNF- is also an
poptotic cytokine. The role of TNF- in irradiation-induced toxicity had been
demonstrated in both TNFR1 knockout mice and WT mice treated with antisense
against TNFR1.11 Targeting the TNF- signaling cascade led to attenuation of
downstream apoptosis. This makes TNF- inhibitors, such as etanercept, attractive
gents for mediating mucositis.
Cyclosporin A (CsA) is an 11 amino acid long fungus-derived peptide.12 It is an
immunosuppressive drug with low myelotoxicity. Its effects were originally thought
to affect mostly T and B lymphocytes,13–15 but have been found to extend to
acrophages as well. CsA decreases human macrophage IL-6 synthesis at the post-
ranscriptional level16 and can decrease reactive oxygen species production in murine
acrophages stimulated by phorbol 12-myristate 13-acetate.17 Other macrophage
functions including antigen presentation,18–20 migration,12,21 and prostaglandin E
production22 can also be down-regulated by CsA. Because macrophages are a major
ource of TNF- production, it reasons that targeting macrophage function is
potentially beneficial in modulating mucositis. Therefore, in this current set of
studies, the possibility of using cyclosporine and etanercept, an antibody against
Open access under the Elsevier OA license.TNF-, to attenuate 5-FU–induced mucositis was examined.
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Current Therapeutic ResearchMETHODS
Animals and Husbandry
Male C57B/6 mice, 10 to 12 weeks old, were used in all studies. All procedures
ere certified according to the UK Animals (Scientific Procedures) Act 1986. The
nimals were purchased from Harlan UK and allowed to acclimatize for 2 weeks
efore use. Both feed (Rat and Mouse Expanded diet, B&K Universal Ltd., North
umberside, United Kingdom) and water (from drinking bottles) were available ad
ibitum. Animal health was monitored daily, and cages were cleaned at regular
ntervals. All animals were kept in individually ventilated cages in a specific patho-
en-free barrier unit. The room was maintained at 21°C (2°C), with a mean (SD)
elative humidity of 55% (10%), and 12-hour day/night cycles. The animals were
dentified by numbered cages and ear punches. For the acute observations, naive mice
ere randomized into groups of 8 for their respective treatments. For the long-term
bservations, 15 animals were randomly assigned to each group.
Experimental Procedures, Clinical Scoring, and Sample
Collection
Etanercept (Lot 34648, Wyeth, Sandwich, United Kingdom) and cyclosporine (Lot
361825, Fluka, Dorset, United Kingdom) were dissolved in phosphate-buffered
aline (PBS) with brief vortexing. The high-dose cyclosporine required brief sonica-
ion to increase solubility. To study the short-term effect of 5-FU–induced mucositis,
tanercept (25 mg/kg) and cyclosporine (50 or 100 mg/kg) were administered once by
P injection 15 minutes after an IP injection of clinical grade 5-FU (Medac, Ham-
urg, Germany) at 500 mg/kg. The doses of etanercept and cyclosporine were selected
ased on internal maximum tolerated dose studies. The dose at this level did not cause
eight loss or clinical signs of adverse effects in the naive animals. The animals were
uthanized 6 hours after administration of 5-FU by cervical dislocation. At the time
f euthanasia, samples of the upper ileum and mid-colon were harvested for analysis.
To study the effects of long-term cyclosporine dosing, all mice were given a second
P injection of 500 mg/kg 5-FU 6 hours after the initial dose of 5-FU. This
ouble-challenge regimen was necessary to generate sufficient crypt death and intes-
inal ulceration. The animals were then dosed daily until day 9 with either 100 mg/kg
yclosporine or PBS. Their weight and signs of diarrhea were noted daily until day 10.
uring the times of peak diarrhea incidence (days 4–10), mice were inspected twice
aily for signs of diarrhea. Scores were recorded as 0, 1, 2, or 3, where 0 is normal
tool consistency, 1 is loose stools, 2 is overt diarrhea with perianal soilage, and 3 is
evere/bloody diarrhea with substantial tail soilage. The daily scores were then
ummed to give a cumulative score over the course of the study. The weight loss of
he animals was also recorded as a surrogate marker for the general health of the
nimals. Mice were euthanized by cervical dislocation. Briefly, the animals were
estrained on a flat surface, and the base of the tail was grasped firmly with 1 hand.
he complete dislocation was achieved with a metal rod placed against the cervical
rea, and followed with a quick backward pull on the tail.
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D. Tung et al.Intestinal Histologic Analysis
Samples of the small (ileum) and large (mid-colon) intestine were removed and
xed in Carnoy’s solution as described by Letari et al.3 Briefly, fixed tissue was
dehydrated through a series of alcohols and xylene steps and then embedded in
paraffin, using a Leica TP1020 tissue processor (Leica Microsystems, Buffalo Grove,
Illinois) and an EG1140H workstation (Leica Microsystems). The fixed small intes-
tines were specially positioned to obtain the ideal orientation of the crypts before
paraffin. From each mouse, a series of intestine segments, approximately 1 cm long,
were placed within a loop of surgical Micropore tape (3M, St. Paul, Minnesota) and
the tape tightened to immobilize the lengths. This allowed the alignment of many
pieces of fixed intestine alongside each other, so that every section contained 10 to 12
well-orientated cross sections. Sections 3 mm thick were cut using a Leica
RM2125RTF microtome (Leica Microsystems), and air-dried on microscope slides
overnight at 37°C. Paraffin blocks were sectioned to generate 2 nonserial sections per
slide. Subsequently, slides were dewaxed in xylene and rehydrated through graded
alcohols to PBS. All sections were then stained with hematoxylin and eosin and
mounted. The number of apoptotic cells, as expressed as apoptotic indices, was
analyzed for each cell position in the crypt and summarized as a cell position plot.
This method divides the surface area of the intestinal crypt into distinct sectors,
making it possible to estimate the percentage of surface of the crypt that is affected.
The investigators were blinded to the treatment groups. Fifty half crypts per mouse
were scored on a cell positional basis, generating 400 frequency scores per group of
8 animals, from which the means were generated.
Data Analysis
The statistical analysis of apoptosis indices was performed using the WinCrypts
oftware that used an extension of the median test.3 At each cell position, the common
median for all the animals was calculated by combining the groups. The individual
values for each animal were classified as being below or above the median. These
values were then cast on a 2 2 contingency table for each position and a 2 test was
pplied. For survival analysis, Cox proportional hazard regression model was used.
he proportional odds model was used to analyze the cumulative diarrhea score. P 
.05 was considered significant in all analysis. The group size was determined using
ower analysis according to the point biserial correlation model with a desired power
f 0.95. The effect size || was calculated to be 0.707, based on a coefficient of
determination value of 0.5.
RESULTS
Effect of Etanercept and Cyclosporine Treatment on the
Apoptotic Index
The effects of cyclosporine and etanercept treatment on intestinal crypt cells
poptosis at 6 hours after 5-FU challenge were examined. The data were summarized
s cell positional plots (Figure 1). In normal tissue, the baseline level of spontaneous
poptosis was low, as reflected in a low apoptotic index throughout the crypt. 5-FU
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Current Therapeutic Researchtreatment induced significant apoptosis in the crypt epithelial cells, especially at cell
positions 1 to 13. Cells in the vicinity of positions 3 to 7 were particularly sensitive.
This region was rich with stem cells that were unable to repair DNA. These apoptotic
cells generally take on a round appearance. The maximum apoptotic index observed
was 25.33% in the PBS-treated animals. At 6 hours after 5-FU challenge, 25 mg/kg
etanercept and 50 mg/kg cyclosporine had no effect on the level of apoptosis.
However, 100 mg/kg cyclosporine decreased the level of apoptosis between cell
positions 6 and 10. This represents 41.6% of the crypt surface showing beneficial
effect.
Effects of Etanercept and Cyclosporine Treatment on Weight
Loss, Diarrhea Score, and Survival
During the long-term observation, weight loss was observed in both cyclosporine-
nd PBS-treated groups after 5-FU challenge (Figure 2). Seven days post-irradiation,
he weight loss in both treatment groups began to plateau. Some animals in the study
ere moribund and were euthanized according to Institutional Animal Care and Use
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Figure 1. Cell positional frequency plots of the apoptotic index in the intestinal crypt 6
hours after systemic exposure to 5-fluorouracil (5-FU). The baseline apoptotic
index of the naive (untreated) animals (●) is also shown. The frequency of
apoptosis in all treatment groups was significantly increased compared with
naïve animals in positions 3 to 14 (P < 0.05). Apoptosis at cell positions 16 to
19 was generally not observed. Etanercept () and low-dose cyclosporine (50
mg/kg) (Œ) treatment had no effect on the frequency of crypt cell apoptosis
after 5-FU exposure. High-dose cyclosporine (100 mg/kg) (‘) given before the
5-FU challenge significantly decreased the amount of apoptosis in positions 6 to
10 compared with the vehicle-treated animals.ommittee recommendation. There was no difference in the rate of weight loss in all
266
D. Tung et al.the treatment groups. There was no difference in the 8 lost between the cyclosporine-
treated animals and the PBS-treated group.
The onset of diarrhea usually took place at the end of day 4 of the model (Figure 3).
Treatment with cyclosporine did not change the diarrhea onset time. At the onset of
the diarrhea, 46.7% of the PBS treated mice had demonstrable diarrhea compared
with 53.3% of the cyclosporine group. There was no significant treatment effect on
the diarrhea scores from both drugs compared with the PBS treated animals. The
diarrhea score for both the PBS- and the cyclosporine-treated groups plateaued on day
7, with a cumulative score of 41 for the PBS group and 50 for the cyclosporine group.
There was no statistical significance between the 2 groups (P  0.05).
The animals in both treatment groups began to die at 7 days after 5-FU challenge
(Figure 4). The survival rate on day 7 was 53% for the PBS-treated animals, and 87%
for the cyclosporine-treated group. Despite this initial higher survival rate in the
cyclosporine group, 100% of the animals were dead in the PBS and cyclosporine
groups by days 9 and 10, respectively. Statistical analysis showed that cyclosporine
treatment offered no benefit on the survival rate compared with PBS control.
DISCUSSION
Mucositis is a common side effect of chemotherapy, which affects a large population
of the oncology patients. The initial toxic symptoms of nausea and vomiting are
usually followed by diarrhea. It occurs in approximately 40% of the standard-dose
chemotherapy patients and 100% of the high-dose chemotherapy and stem cell or
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Figure 2. Effects of cyclosporine (●) treatment on weight loss after 5-fluorouracil chal-
lenge. The animals received daily dosing of either cyclosporine or vehicle. The
weight loss in the cyclosporine-treated animals were not significantly different
from that in the vehicle-treated animals throughout the study (*P < 0.05).bone marrow transplantation patients.23,24 Many of these symptoms are thought
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Current Therapeutic Researchto be associated with epithelial damage, which is preceded by microvasculature
damage.25
There is a strong rationale for examining the potential therapeutic role of etaner-
ept and cyclosporine in mucositis protection. Proinflammatory cytokines, including
NF-, have been implicated in the pathogenesis of mucositis.26–29 In mouse oral
ucosa, irradiation induced up-regulation of TNF- and COX-2.30 Antisense treat-
ment against TNFR1 has demonstrated radioprotective effects.31 Macrophages are
ne of the key cell types that mediate inflammatory responses. Cyclosporine has been
hown to down-regulate proinflammatory cytokine production by both human and
odent macrophages.32–34 Thus, the potential therapeutic effects of etanercept and
yclosporine were studied in the current set of experiments.
In our studies, we quantified the level of apoptosis in the intestinal crypt caused
y systemic 5-FU challenge. The apoptotic index increased toward the apical surface
f the crypt. Cyclosporine (50 mg/kg) and etanercept (25 mg/kg) did not affect the
evel of apoptosis. However, 100 mg/kg cyclosporine was effective in significantly
own-regulating apoptosis in the intestinal crypt. These doses were chosen based on
afety data derived from internal maximum tolerated dose studies. Even though
NF- has been considered a main driving cytokine in many inflammatory pro-
esses,29 its pivotal role in mucositis pathology had been controversial. In our current
tudy, it is possible that TNF- does not play a large role in the early apoptotic
Vehicle
100mg/kg Cyclosporine
60
50
40
30
20
10
0
0 2 4 6 8 10 12
Days
C
um
ul
at
iv
e 
D
ia
rr
he
a 
S
co
re
Figure 3. Effects of cyclosporine treatment on the diarrhea severity of the 5-fluorouracil
(5-FU)–challenged animals. The cumulative diarrhea score increased exponen-
tially 3 days after 5-FU challenge. The severity of diarrhea in the vehicle- and
cyclosporine-treated animals plateaued after 7 days. Cyclosporine had no sig-
nificant effect on the diarrhea severity.rocess in the intestinal crypt after 5-FU challenge, but the examination of the
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D. Tung et al.temporal role of TNF- is beyond the scope of this article. Our observations echo those
of Haagen et al.30 who questioned the role of TNF- in other models of mucositis.
The authors reported that infliximab treatment did not affect irradiation-induced oral
mucositis in the mouse.30 Even though it had been suggested that the lack of
infliximab treatment effects might be attributed to species specificity,35 the doses
used in the experiment had been shown to be effective in other murine models. It is
possible that other parallel inflammatory pathways are influencing the response.
Based on the observation that 100 mg/kg cyclosporine affected the apoptosis of the
intestinal epithelial cells, we examined the long-term effects of high-dose cyclospo-
rine on various clinical parameters in a more severe disease state. In this paradigm,
cyclosporine treatment did not improve the survival of the animals. The weight loss
and cumulative diarrhea score were also not affected by cyclosporine treatment
compared with the PBS-treated animals. Both parameters began to plateau at 7 days
post-challenge. According to a priori power analysis using the point biserial corre-
lation model, a sample size of 13 (  0.05) is adequate to provide a power of 0.958
o detected a significant difference of P  0.05 between the treatment groups.
ecause 15 animals were assigned to each group, this study was powered adequately
o support a meaningful analysis. One factor worthy of further investigation is a more
requent dosing regimen of etanercept and cyclosporine. Even though both com-
ounds were dosed within the maximum tolerated dose, it is possible to dose the
nimals at a higher frequency and still remain within the established safety margin.
nother parameter that can be explored is the effect of challenging the animals with
lower dose of 5-FU. It is possible that the severity of the intestinal damage caused
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Figure 4. Effects of cyclosporine treatment on the survival of the 5-fluorouracil– chal-
lenged animals. Fifteen animals were assigned to each treatment group at the
beginning of the study. Death of the animals was first observed at day 7 after
challenge. Daily treatment with cyclosporine had no effect on the survival rate
of the animals throughout the study.y the current dose is too high for these immunomodulators to down-regulate.
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Current Therapeutic ResearchIn this study, we quantified 5-FU–induced local changes in the intestinal epithe-
ium, which led to subsequent weight loss and diarrhea. We further demonstrated the
ack of association between intestinal epithelial cell apoptosis and the survival of the
nimals. Even though some investigators reported up-regulation of TNF- and
ctivation of macrophages in mucositis, treatment with etanercept and cyclosporine
id not affect many parameters. It is possible that the increase in TNF- expression
is incidental, and other pathways can compensate for the TNF- inhibition. The
nteraction of different cytokines and inflammatory cell types is complex, and it is
ikely that targeting TNF- alone is not sufficient to affect these pathologies. Further
investigation would be required to establish the relationship between various proin-
flammatory cytokines and these disease parameters.
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